Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

doi:10.5246/jcps.2017.06.051

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (6): 460-464.DOI: 10.5246/jcps.2017.06.051

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Monisola I. Ikhile^1*, Foluso O. Osunsanmi², Andy R. Opoku², J. Catherine Ngila¹

1. Department of Applied Chemistry, University of Johannesburg, Doornfontein Campus, Johannesburg 2028, 17011, South Africa
2. Department of Biochemistry and Microbiology, University of Zululand, private Bag X1001, KwaDlangezwa 3886, South Africa

收稿日期:2017-03-15 修回日期:2017-04-20 出版日期:2017-06-29 发布日期:2017-05-18
通讯作者: Tel.: +27-11-559-6425, E-mail: mikhile@uj.ac.za; alafin21@yahoo.com
基金资助:
Global Excellence and Stature (GES), 2016, University of Johannesburg.

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Monisola I. Ikhile^1*, Foluso O. Osunsanmi², Andy R. Opoku², J. Catherine Ngila¹

1. Department of Applied Chemistry, University of Johannesburg, Doornfontein Campus, Johannesburg 2028, 17011, South Africa
2. Department of Biochemistry and Microbiology, University of Zululand, private Bag X1001, KwaDlangezwa 3886, South Africa

Received:2017-03-15 Revised:2017-04-20 Online:2017-06-29 Published:2017-05-18
Contact: Tel.: +27-11-559-6425, E-mail: mikhile@uj.ac.za; alafin21@yahoo.com
Supported by:
Global Excellence and Stature (GES), 2016, University of Johannesburg.

摘要/Abstract

摘要：

Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (3–10), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine (3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine (4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine (5), N-(ferrocenylformidene)-3-ferrocenylimine (6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine (7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine (8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine (9), N-(ferrocenylformidene)-4-ferrocenylimine (10) on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds (3–10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline (compound 1) and 4-ferrocenylaniline (compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.

关键词: Ferrocene, Imine, Antiplatelet aggregation, Thrombin, Platelet

Abstract:

Key words: Ferrocene, Imine, Antiplatelet aggregation, Thrombin, Platelet

中图分类号:

R973

Supporting:

Monisola I. Ikhile, Foluso O. Osunsanmi, Andy R. Opoku, J. Catherine Ngila. Antiplatelet aggregation activity of some ferrocenylphenylimine compounds[J]. 中国药学(英文版), 2017, 26(6): 460-464.

Monisola I. Ikhile, Foluso O. Osunsanmi, Andy R. Opoku, J. Catherine Ngila. Antiplatelet aggregation activity of some ferrocenylphenylimine compounds[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(6): 460-464.

参考文献

[1] Davi, G.; Patrono, C. N. Engl. J. Med. 2007, 357, 2482–2494.

[2] Libby, P.; Theroux, P. Circulation. 2005, 111, 3481–3488.

[3] Meadows, T.A.; Bhatt, D.L. Circ. Res. 2007, 100, 1261–1275.

[4] Gachet, C. Thromb. Haemost. 2008, 99, 466–472.

[5] Patron, C.; Garcia-Rodriguez, L.A.; Landolfi, R.; Baigent, C. N. Engl. J. Med. 2005, 353, 2373–2383.

[6] Mangin, P.; Yap, C.L.; Nonne, C.; Sturgeon, S.A.; Goncalves, I. Blood. 2006, 107, 4346–4353.

[7] Adam, F.; Bouton, M.C.; Huisse, M.G.; Jandrot-Perrus, M. Trends. Mol. Med. 2003, 9, 461–464.

[8] Auer, J.; Berent, R.; Lassnig, E.; Weber, T.; Maurer, E.; Eber, B. Herz. 2003, 28, 393–403.

[9] Burke, A.; Smyth, E.; Fitzgerald, G.A. 26: analgesic antipyretic and anti-inflammatory agents, in the pharma-cological basis of therapeutic (Goodman and Gilman’s), New York, McGraw-Hill. 2006, 11, 671–716.

[10] Michelson, A.D. Circulation. 2004, 110, 489–493.

[11] Coleman, K.S.; Turberville, S.; Pascu, S.I.; Green, M.L.H. J. Organomet. Chem. 2005, 690, 653–658.

[12] Ornelas, C. New J. Chem. 2011, 35, 1973–1985.

[13] Qin, W.; Long, S.; Panunzio, M.; Biondi, S. Schiff bases: Molecules. 2013, 18, 12264–12289.

[14] Ikhile, M.I.; Ngila, J.C. Chin. J. Inorg. Chem. 2015, 31, 2079–2088.

[15] Guide for the care and use of laboratory animals. NIH publication No. 85–23, Revised 1985.

[16] Tomita, T.; Umgegaki, K.; Hayashi, E. J. Pharmacol. Methods. 1983, 10, 31–44.

[17] Mekhfi, H.; Haouari, E.I.; Legssyer, A. J. Ethnopharmacol. 2004, 94, 317–322.

[18] Willoughby, S.; Holmes, A.; Loscalzo, J. Eur. J. Cardiovasc Nurs. 2002, 1, 273–288.

[19] Gupta, S.R.; Mourya, P.; Singh, M.M.; Singh, V.P. J. Organometal. Chem. 2014, 767, 136–143.
[20] Osunsanmi, F.O.; Soyinbe, O.S.; Ogunyinka, I.B.; Mosa, R.A.; Ikhile, M.I. Ngila, J.C.; Shode, F.O.; Opoku, A.R. J. Med. Plants Res. 2015, 9, 647–854.
[21] Fabre, J.; Gurney, M.E. Mol. Bio. Syst. 2010, 6, 305–315.

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价